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The Prostate Health Index adds 
predictive value to multi-parametric 
MRI in detecting significant prostate 
cancers in a repeat biopsy population
V. J. Gnanapragasam1,2,3, K. Burling4, A. George1, S. Stearn1, A. Warren5, T. Barrett6,7, B. Koo6, 
F. A. Gallagher6,7, A. Doble2,3, C. Kastner2,3 & R. A. Parker8
Both multi-parametric MRI (mpMRI) and the Prostate Health Index (PHI) have shown promise in predicting 
a positive biopsy in men with suspected prostate cancer. Here we investigated the value of combining both 
tests in men requiring a repeat biopsy. PHI scores were measured in men undergoing re-biopsy with an 
mpMRI image-guided transperineal approach (n = 279, 94 with negative mpMRIs). The PHI was assessed 
for ability to add value to mpMRI in predicting all or only significant cancers (Gleason ≥7). In this study 
adding PHI to mpMRI improved overall and significant cancer prediction (AUC 0.71 and 0.75) compared to 
mpMRI + PSA alone (AUC 0.64 and 0.69 respectively). At a threshold of ≥35, PHI + mpMRI demonstrated a 
NPV of 0.97 for excluding significant tumours. In mpMRI negative men, the PHI again improved prediction 
of significant cancers; AUC 0.76 vs 0.63 (mpMRI + PSA). Using a PHI≥35, only 1/21 significant cancers 
was missed and 31/73 (42%) men potentially spared a re-biopsy (NPV of 0.97, sensitivity 0.95). Decision 
curve analysis demonstrated clinically relevant utility of the PHI across threshold probabilities of 5–30%. In 
summary, the PHI adds predictive performance to image-guided detection of clinically significant cancers 
and has particular value in determining re-biopsy need in men with a negative mpMRI.
The Prostate Health Index (PHI) was developed by incorporating the pro-2PSA, free PSA and total PSA into a 
mathematical algorithm1. Le et al. published one of the first papers evaluating the PHI in 2034 men and found 
that it significantly improved prediction of a positive biopsy compared to PSA in the range of 2.5–10 ng/ml2. Since 
then, many others have consistently shown similar results with different PSA ranges and across different popula-
tions3–6. Most recently, the PHI and 4K score were evaluated in the Swedish STHLM2 trial and both were shown 
to increase prediction of aggressive cancers and spare about a third of men an unnecessary biopsy7. The PHI is 
now approved by the US FDA and been adopted into the US NCCN guidelines8,9.
Despite these promising results, the PHI is not yet in widespread use and an unanswered question is how it fits 
with the increasing use of pre-biopsy imaging. Multi-parametric MRI (mpMRI) has emerged as an important tool 
for both identifying men who need a biopsy and where to target the needles10,11. This is particularly important in 
a repeat biopsy population where mpMRI guidance has shown superiority over other approaches in predicting a 
positive finding when a prior biopsy has been negative or thought to have under estimated the disease burden12. 
mpMRI however, cannot always reliably exclude cancers. Indeed, systematic reviews have shown a wide range of 
negative predictive values (NPV) for even significant cancer detection (63–98%)13,14. Work in our own unit has 
shown very similar findings in a repeat biopsy population with NPV of 66–89% depending on radiologist experi-
ence15,16. As a result, many men are likely to still undergo a repeat prostate biopsy despite a negative mpMRI. This 
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is an unnecessary risk to patients and significant waste of resources. In this context a blood based assay (such as 
the PHI) to identify men who will most benefit from an mpMRI guided biopsy would be very useful.
In this study we explored the potential value of the PHI in the context of image guided repeat biopsies. Our 
specific aims were to assess the value of the PHI in predicting a positive mpMRI scan, test its incremental value 
to mpMRI in predicting cancers and its utility in deciding which men with a negative mpMRI should proceed 
with a re-biopsy.
Materials and Methods
Patients, imaging and biopsy data. Between 2013 and 2015, men due to undergo a repeat prostate biopsy 
by a transperineal approach were recruited into a prospective study (Ethics 03/018 - NRES Committee East of 
England, UK) in our centre with informed consent obtained from all participants. The experimental protocol for 
patient recruitment, sample handling and processing, use of imaging and data were approved by this body. All 
methods were therefore performed in accordance with the relevant guidelines and regulations.
All men had previously had at least 1 prostate biopsy and required re-biopsy because of ongoing suspicion 
of cancer or where cancer grade had thought to be underestimated. All had a prior mpMRI and proceeded to 
biopsy regardless of whether a target lesion was identified or not. For the purposes of this study men with any 
suspicion of extra capsular disease (on mpMRI), infection, prostatitis or previous prostate surgery/treatment 
were excluded. A total of 279 men were included in this analysis. Patients underwent mpMRI on a 1.5T MR450 
or 3T Discovery MR750-HDx system (GE Healthcare, USA) with a multi-channel surface phased array coil, 
including standard anatomical and functional diffusion-weighted imaging using multiple b-values, as previously 
described17. Image acquisition and processing was performed in accordance with standard clinical mpMRI pro-
tocols in the Department of Radiology, Addenbrookes Hospital. T2W and DWI sequences were evaluted and 
scored using a Likert scale of cancer probability, based on the Prostate Imaging Reporting and Data (PI-RADS) 
descriptors developed by the European Society of Urogenital Radiology (ESUR)18. This study however pre-dated 
the PI-RADS 2 revision. All images were reviewed and discussed in a Multi-Disciplinary Team (MDT) meeting 
before biopsy. Prostate volumes were calculated from mpMRI images. The contours of mpMRI defined lesions 
(Likert 3–5) were drawn on the BiopseeTM fusion platform (Medcom, Germany). No lesion or Likert 1–2 lesions 
were considered mpMRI negative for this study. 24 sectoral biopsies + 2 from each target area using image fusion 
guidance (where applicable) were taken using a previously published standardised template (Ginsberg protocol)19. 
Men without mpMRI lesions (mpMRI negative) had 24 sectoral biopsies taken only. All procedures were done by 
1 of 3 urologists with several years’ experience of transperineal biopsy. Biopsy samples were processed through a 
single pathology laboratory and reported by specialist uro-pathologists (using ISUP 2005) and re-reviewed in the 
(MDT) meeting before a final grade and diagnosis was assigned.
PHI assay. The protocol for performing the PHI assay was performed according to the manufactures guide-
lines and recommendations (Beckman Coulter). Blood was taken prior to biopsies, and at least four weeks after 
any prostate manipulation. Samples were centrifuged and frozen at − 80c within three hours. PHI assays were per-
formed on the Beckman Coulter Access autoanalyser. Quality Assurance samples were analysed before and after 
each batch to ensure the validity of the results. All reagents, calibrators and QC’s were purchased from Beckman 
Coulter. All QC results were within Beckman Coulter’s target ranges.
Statistical analysis. The PHI was evaluated in the primary cohort for predicting (i) any cancer, and (ii) 
any significant cancer in combination with mpMRI. For this study, and to be consistent with current guideline 
definitions of risk, we defined clinical significance as any Gleason sum ≥ 7 disease8,20. No PHI threshold was 
pre-determined before the study. Logistic regression models were used to generate receiver operative curves for 
the variables of mpMRI alone, mpMRI + PSA and mpMRI + PHI. Differences in area-under-the-curve (AUC) 
were calculated using Delong’s method in the “pROC” package in R software21,22. Diagnostic test statistics (sensi-
tivity, specificity, positive predictive value [PPV], negative predictive value [NPV], number of unnecessary biop-
sies, and number with cancer missed) were derived to identify the optimum PHI threshold for cancer detection. 
This analysis sequence was then repeated in the cohort of men with a negative mpMRI. Decision curve analysis 
(DCA) were used to investigate the clinical value of the test strategies23. Finally we included a sensitivity analysis 
to exclude men who already had a cancer diagnosis before re-biopsy and retested our results. Analysis was per-
formed using R software version 3.2.3 and SPSS version 2122,24.
Results
Cohort description and value of PHI in predicting a mpMRI lesion. The demographic details of the 
primary cohort are shown in Table 1. 279 men were included the majority of whom had 1–2 prior prostate biop-
sies. Most had no previous cancer diagnosis, although 65/279 (23%) underwent a repeat biopsy to exclude more 
extensive disease. Table 2 details the distribution of the PHI components stratified by mpMRI findings and pre-bi-
opsy histology. At mpMRI 185/279 (66%) men had a Likert ≥ 3 lesion and 94 (34%) had no lesion or only Likert 
1–2. We first tested if the PHI could predict if an mpMRI would be positive. PHI scores were generally higher in 
men with a mpMRI lesion (Table 2). However, using the PHI only marginally increased predictive value com-
pared to PSA; Area under the curve (AUC) for PHI of 0.60 [0.53–0.67] for any Likert score (vs 0.47 [0.40–0.54] 
for PSA) and 0.59 [0.52–0.66] for a Likert 4/5 lesion (vs. 0.51 [0.44–0.58] for PSA). These results suggest that the 
PHI is unlikely to be useful as a triaging test in deciding if an mpMRI will be positive.
Value of the PHI in addition to mpMRI in predicting biopsy outcome. Following repeat biopsies, 
95 (34%) men had a benign outcome and 184 (66%) had cancers detected of whom 94 (34%) were Gleason ≥ 7. 
The PHI alone was a significant predictor for any cancer (OR 1.018, 95% CI 1.004–1.032, p = 0.01) and significant 
cancers (OR 1.025, 95% CI 1.013–1.038, p < 0.0001) after adjusting for mpMRI in logistic regression. Adding 
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PHI to mpMRI also improved predictive performance for overall cancer detection; AUC 0.71 [0.61–0.76] vs. 
0.64 (mpMRI) (Fig. 1A). In comparison, adding PSA alone to mpMRI did not appreciably alter predictive per-
formance (AUC 0.64). We next focused on prediction of only significant cancers. Adding PHI to mpMRI, again 
showed a much greater improvement in predictive performance (AUC 0.75, vs. 0.64) (Fig. 1B). In contrast, adding 
PSA to mpMRI only marginally improve positive biopsy prediction compared to mpMRI alone (AUC 0.69 vs. 
0.64) (Fig. 1B). These results were very similar and conclusions unchanged after excluding patients with previous 
cancer. To contextualise the improvement in predictive value, we plotted decision curves. For overall cancer 
detection, decision curve analysis (DCA) showed that the PHI only added value to mpMRI in decision making 
for threshold probabilities of 45–85% which would be unlikely to be of clinical use (Fig. 2A). DCA for significant 
cancers, however, showed that the PHI did add value with a net benefit across threshold probabilities as low as 
15% which would be clinically useful (Fig. 2B). These threshold probability ranges were identical in sensitivity 
analysis excluding patients with previous cancer. To determine an optimal PHI level we next tested different 
cut-off values in detecting or missing cancers. For overall cancer prediction no specific PHI cut-off showed prom-
ise (Supplementary Table 1). For significant cancers, however, a PHI ≥ 35 would have detected all but one tumour 
with a NPV of 0.97 and sensitivity of 0.99 (Table 3). After excluding patients with previous cancer, the results were 
again very similar.
Use of the PHI score in determining biopsy need in men with a negative mpMRI. Amongst the 
94 negative mpMRI, 52 cancers were diagnosed including 21 Gleason ≥ 7. In this group, the PHI had an AUC of 
0.66 for overall cancer detection (95% CI 0.55–0.77), but was particularly useful in predicting significant cancers 
(AUC 0.76, 95% CI 0.64 – 0.87) and outperformed PSA and PSA density (Fig. 3A,B and Supplementary Table 2). 
After excluding patients with a prior cancer diagnosis, the PHI AUC increased to 0.79 (95% CI 0.65 to 0.93) for 
predicting significant cancers. A PHI threshold of ≥ 35 showed the best discriminatory value missing only 1/21 
Gleason ≥ 7 tumour and potentially sparing 42% of the remaining cohort from a biopsy episode (31/73) (Table 4). 
Of note the missed cancer only involved 10% of a single core out of 24 samples and therefore represented min-
imal disease. Finally, to assess the clinical improvement in predictive value, we repeated a DCA. This again did 
not show much benefit for overall cancer detection, but did so for predicting significant cancers across threshold 
probabilities from 5–30% (Fig. 4A,B). This is a clinically very relevant uncertainty range when deciding if a biopsy 
is necessary with a negative mpMRI. A sensitivity analysis excluding patients with previous cancer gave very 
similar results in the DCA.
Patient data (n = 279) Median (range)
Age (years) 66 (45–80)
Prostate volume (mls) 52 (11–230)
mpMRI lesion
 No target/Likert 1–2 94 (34%)
 Likert 3 53 (19%)
 Likert 4 71 (25%)
 Likert 5 61 (22%)
Prior cancer on biopsy
 No 214 (77%)
 Yes – Gleason 6 60 (22%)
 Yes – Gleason 7* 5 (2%)
Table 1. Descriptive characteristics of the primary study cohort prior to template biopsies. mpMRI 
(multi-parametric MRI). *Gleason 7 (3 + 4) cases before repeat biopsy involved ≤ 2 cores with < 10% tumour 
involvement.
Variable 
median (range)
mpMRI Pre- biopsy histology
No lesion/Likert 1–2 Likert 3–5 Likert 4–5 No cancer Gleason ≥6 Gleason ≥7
(n = 94) (n = 185) (n = 132) (n = 214) (n = 60) (n = 5)
tPSA 9.37 (2.10–30.4) 9.14 (0.30–40.5) 9.31 (0.30–40.5) 9.60 (0.30–40.5) 9.08 (0.95–22.2) 7.69 (4.20–10.6)
Free PSA 1.48 (0.30–9.30) 1.20 (0.10–5.62) 1.20 (0.10–5.62) 1.36 (0.10–9.30) 1.30 (0.23–5.20) 0.60 (0.30–1.07)
p2PSA 18.6 (4.80–143.2) 18.3 (2.77–96.3) 17.8 (2.77–96.3) 18.6 (4.77–143.2) 18.5 (2.77–58.7) 10.4 (9.71–15.7)
PHI 38.2 (13.1–214.1) 44.4 (11.7–219.6) 45.3 (11.7–219.6) 40.5 (13.1–219.6) 44.7 (11.7–135.5) 38.1 (33.3–119.4)
PSA density 0.19 (0.05–0.64) (n = 71)
0.28 (0.02–1.57) 
(n = 148)
0.29 (0.02–1.57) 
(n = 109)
0.24 (0.02–1.57) 
(n = 169)
0.25 (0.06–0.76) 
(n = 47)
0.24 (0.08–0.34) 
(n = 3)
Table 2. Distribution of median and range of PHI derivative components, derived PHI score and PSA 
density in the whole cohort (n = 279) stratified by pre-repeat biopsy mpMRI findings and histology. Data 
on PSA density was not available in some of the cohort.
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Discussion
Research into new diagnostics in prostate cancer have focussed on two main areas (i) mpMRI for image guided 
biopsies and (ii) biomarkers to better predict the presence of cancer. To date, there has been a paucity of research 
that has combined these two aspects in well-structured cohort studies, particularly, in the re-biopsy setting25,26. 
As a result, there is significant uncertainty as to how to maximise the benefits of both in clinical practice. 
Head-to-head comparisons have not surprisingly shown that biomarkers alone fare worse than imaging in pre-
dicting cancers25,27,28. Only one study has tested both imaging and the PHI in the re-biopsy context. Porpiglia 
et al. compared performance of the PHI and PCA3 with mpMRI in a repeat biopsy population29. In this study, 
neither PHI nor PCA3 added to the value of mpMRI in predicting cancers. Crucially however, the biopsies were 
done blinded to the mpMRI findings and were performed transrectally. We have previously shown that image 
guided and transperineal biopsies are significantly better in detecting cancers in the re-biopsy context and are a 
better reference test12. Indeed, a recent UK Health Technology Assessment of the PHI identified the lack of good 
biopsy reference standards as a weakness of previous comparative studies25. Other identified uncertainties from 
the paper included the value of the PHI in (i) predicting an mpMRI lesion, (ii) predicting significant cancers 
and (iii) the optimal sequence for using the PHI and mpMRI in practice25. Our current study addresses all these 
uncertainties in its design and is the first to unify a comprehensive mpMRI fusion guided transperineal biopsy 
protocol with evaluation of the PHI as a serum diagnostic biomarker.
Figure 1. Area under the curve (AUC) comparison of performance of the PHI in combination with mpMRI in 
identifying men who will be positive on a repeat biopsy for (A). Any cancer and (B). Significant (Gleason sum ≥ 7) 
cancers. (n = 279). Purple –reference, Yellow – mpMRI only, Green - mpMRI + PSA, Blue - mpMRI + PHI.
Figure 2. Decision curve analysis comparing the added value of the PHI test in addition to mpMRI in 
identifying men who will be positive on a repeat biopsy for (A). Any cancer and (B). Significant (Gleason sum 
≥ 7) cancers. (n = 279).
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mpMRI is known to have a high specificity and sensitivity for detecting clinically significant cancers30,31. 
However, it is an expensive and resource intensive investigation and unlikely to be suitable as a screening tool. 
An important question therefore is if the PHI (or other biomarkers) might be used as a triaging test to predict a 
positive mpMRI. In this study, although PHI scores were generally higher when an mpMRI was positive, it was 
not reliable in predicting a lesion. One caveat is that these findings are in a re-biopsy cohort and it may not equally 
apply in a biopsy naïve population. We next asked if the PHI could improve mpMRI predictive performance in 
the context of transperineal image guided biopsies. In terms of overall detection, our findings agree with those of 
Porpiglia et al. in that the PHI added little additional clinical value29. However, the PHI did improve predictive 
performance for significant cancers, particularly using a cut-off ≥ 35 and this is likely to be clinically relevant. This 
level was not predefined for this study, instead it was derived by testing different thresholds to identify the optimal 
value. Indeed, no previous study has established the optimal PHI for a repeat biopsy population, although one 
study (using a non-image guided approach) identified a correlation with significant cancer detection and a PHI 
Decision to biopsy
Sensitivity 
(95% CI)
Specificity  
(95% CI)
PPV  
(95% CI)
NPV  
(95% CI)
No. of non-
significant biopsies
No. of missed 
Gl ≥ 7
mpMRI positive 0.78 (0.68–0.86) 0.39 (0.32–0.47) 0.39 (0.32–0.47) 0.78 (0.68–0.86) 112 21
mpMRI positive or PHI ≥ 25 0.99 (0.94–1) 0.04 (0.02–0.08) 0.34 (0.29–0.40) 0.89 (0.52–1) 177 1
mpMRI positive or PHI ≥ 30 0.99 (0.94–1) 0.11 (0.067–0.16) 0.36 (0.30–0.42) 0.95 (0.76–1) 165 1
mpMRI positive or PHI ≥ 35 0.99 (0.94–1) 0.17 (0.12–0.23) 0.38 (0.32–0.44) 0.97 (0.84–1) 154 1
mpMRI positive or PHI ≥ 40 0.95 (0.88–0.98) 0.25 (0.19–0.32) 0.39 (0.33–0.46) 0.90 (0.79–0.97) 138 5
Table 3. Diagnostic test statistics modeling each of the different strategies incorporating various PHI 
thresholds and detection rates for significant cancers (Gleason sum ≥7). Non-significant biopsies combine 
negative biopsies and those detecting Gleason sum 6 cancers only. mpMRI positive refers to lesions of Likert 3 
or greater.
Figure 3. Area under the curve (AUC) comparison of performance of the PHI in men with a negative mpMRI 
in identifying men who will be positive on a repeat biopsy for (A). Any cancer AUC 0.66 (95% CI 0.55 to 0.77) 
and B. Significant (Gleason sum ≥ 7) cancers 0.76 (95% CI 0.64 to 0.87). (n = 94). Green – reference, Blue – PHI.
Decision to 
biopsy
Sensitivity  
(95% CI)
Specificity  
(95% CI)
PPV  
(95% CI)
NPV  
(95% CI)
No. of non-
significant biopsies
No. of missed 
Gl ≥ 7
PHI ≥ 25 0.95 (0.76–1) 0.11 (0.049–0.2) 0.24 (0.15–0.34) 0.89 (0.52–1) 65 1
PHI ≥ 30 0.95 (0.76–1) 0.27 (0.18–0.39) 0.27 (0.18–0.39) 0.95 (0.76–1) 53 1
PHI ≥ 35* 0.95 (0.76–1) 0.42 (0.31–0.55) 0.32 (0.21–0.45) 0.97 (0.84–1) 42 1#
PHI ≥ 40 0.76 (0.53–0.92) 0.64 (0.52–0.75) 0.38 (0.24–0.54) 0.90 (0.79–0.97) 26 5
Table 4. Diagnostic test statistics modeling each of the different strategies incorporating various PHI 
thresholds and detection rates for significant cancers (Gleason sum ≥7) in men with a negative mpMRI 
(n = 94). *The model of proceeding to biopsy only if the PHI was ≥ 35 gave the optimum performance. Non-
significant biopsies combine negative biopsies and those detecting Gleason sum 6 cancers only. #Missed tumour 
was Gleason 3 + 4 in only 1/24 cores, < 10% core involvement.
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≥ 5532. A PHI ≥ 35 is higher than that reported in first biopsy studies but is actually the threshold recommended 
by the NCCN guidelines8.
Re-biopsies in men with a negative mpMRI is controversial and there is currently no consensus or agreed 
approach. Many urologists might not advocate a re-biopsy especially if the PSA density is low33. mpMRI reporting 
however can be highly variable and the rate of significant cancers despite a negative mpMRI is not inconsidera-
ble11,13,16,30. In our cohort (with experienced uro-radiologists) significant cancers were found in 22% of mpMRI 
negative men. Amongst these men, a PHI ≥ 35 identified all but one very low volume and minimal Gleason ≥ 7 
cancer. Decision curve analysis further suggested that the PHI was clinically useful across a relevant threshold of 
uncertainty. In practice nearly half of men with a negative mpMRI men in this study might have potentially been 
safely spared a biopsy.
Our study has some inherent limitations. It is single centre and includes relatively modest numbers. Our study 
however benefit from a well-characterised cohort, use of image-guided transperineal biopsies and being under-
taken by an experienced multi-disciplinary diagnostic team12,15–17. The findings may not be similar in less expe-
rienced units or with other biopsy approaches and further validation in a multi-institutional setting is needed. 
Our study was also based in a repeat biopsy population and needs re-testing in a first biopsy population, which we 
are currently undertaking. Our mpMRI didn’t include dynamic contrast enhancement, however we note that its 
added value to lesion scoring is currently doubtful34. Our study also did not use the updated PIRADS version 2 as 
our cohort predated this publication. Our criteria for clinical significance was based on any detection of Gleason 
7 disease and did not account for the number of cores positive or percentage cores positive. Our rationale was 
based on the fact that current risk stratification criteria (UK NICE, AUA, NCCN) do not yet include these latter 
elements and our sample size was not large enough to further sub-divide the cohorts. Finally, we did not employ 
study-specific repeat review of all imaging and histology. However, all our results are re-reviewed in a multidisci-
plinary meeting setting and this is more representative of real world clinical pathways.
In summary we show for the first time that combing the serum biomarker PHI to imaging (mpMRI) improves 
the predictive ability for detection significant prostate cancer but not for overall cancer detection. The PHI may 
have particular value in identifying men who do need a biopsy when the mpMRI is negative. In this regard, the 
PHI might help reduce the number of unnecessary biopsies especially where there is either limited or evolv-
ing experience in reading mpMRIs. These findings are preliminary and do need further validation in future 
larger studies. However they do suggest first evidence of a complementary role for the PHI assay with mpMRI in 
image-guided re-biopsies. Our next studies will explore whether this relationship holds true in a first biopsy pop-
ulation. This will be important in the context of on-going studies which are evaluating both the PHI and mpMRI 
as first line screening tests.
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